Rapport Therapeutics' Lead ASM Forecast at $2.0 Billion Peak Sales
Analyst Myles Minter projects Rapport Therapeutics’ lead ASM may reach $2.0 billion in peak global sales. This estimate was highlighted alongside Praxis Precision’s $4.0 billion forecast during commentary on Xenon Pharmaceuticals’ Phase 3 X-TOLE2 seizure trial results.
1. Analyst Projection for RAPP
Analyst Myles Minter projects that Rapport Therapeutics’ lead antiseizure medication could achieve up to $2.0 billion in peak global sales, reflecting strong commercial potential.
2. Comparative Seizure Market Context
This projection was raised in the context of Xenon Pharmaceuticals’ Phase 3 X-TOLE2 trial success, where peer Praxis Precision’s ASM was estimated at over $4.0 billion, underscoring RAPP’s market positioning.
3. Investor Valuation Implications
Investors may revisit RAPP’s valuation and pipeline prospects as high-profile Phase 3 data from a key competitor highlights the commercial upside of novel seizure therapies.